Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir
Leonardo Calza, Marco Borderi, Vincenzo Colangeli, Teresa Miani, B Nuti, Isabella Bon, Tiziana Lazzarotto, Pierluigi Viale
Abstract
In the present study, the mean increases reported in weight, BMI, and waist circumference after 12 months were comparable in naive patients starting abacavir/ lamivudine/dolutegraviror tenofovir alafenamide/emtricitabine/bictegravir.
Topics & Concepts
DolutegravirAbacavirEmtricitabineMedicineTenofovir alafenamideVirologyLamivudineHuman immunodeficiency virus (HIV)TenofovirViral loadAntiretroviral therapyHepatitis B virusVirusHIV-related health complications and treatmentsHIV/AIDS drug development and treatmentPneumocystis jirovecii pneumonia detection and treatment